Galena生物制药

SLS NASDAQ
0.1291
-0.0108
-7.72%
盘后: 0.1368 +0.0077 +5.96% 19:59 07/15 EDT
开盘
0.1400
昨收
0.1399
最高
0.1413
最低
0.1222
成交量
4,073.35万
成交均量(3M)
1,421.07万
52周最高
2.460
52周最低
0.1021
换手率
31.90%
市值
1,648.49万
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Galena生物制药 SLS股票价格,Galena生物制药股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

SELLAS Life Sciences Group, Inc., formerly Galena Biopharma, Inc., is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company's NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company's therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient's own immune system.
展开 >

最近浏览

名称
价格
涨跌幅